Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1970
mi
from 98109
Nashville, TN
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1970
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1890
mi
from 98109
Houston, TX
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2348
mi
from 98109
Richmond, VA
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2348
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1681
mi
from 98109
Milwaukee, WI
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1681
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1782
mi
from 98109
Little Rock, AR
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1782
mi
from 98109
Little Rock, AR
Click here to add this to my saved trials
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated:  12/31/1969
7763
mi
from 98109
Kingswood,
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Status: Enrolling
Updated: 12/31/1969
7763
mi
from 98109
Kingswood,
Click here to add this to my saved trials
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients
Clinical Protocol to Investigate the Efficacy of Amlexanox vs. Placebo for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics
Status: Enrolling
Updated:  12/31/1969
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients
Clinical Protocol to Investigate the Efficacy of Amlexanox vs. Placebo for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics
Status: Enrolling
Updated: 12/31/1969
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1116
mi
from 98109
Phoenix, AZ
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1116
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1041
mi
from 98109
Encinitas, CA
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1041
mi
from 98109
Encinitas, CA
Click here to add this to my saved trials
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
681
mi
from 98109
San Francisco, CA
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
681
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2544
mi
from 98109
Orlando, FL
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2544
mi
from 98109
Orlando, FL
Click here to add this to my saved trials
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2005
mi
from 98109
Lexington, KY
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2005
mi
from 98109
Lexington, KY
Click here to add this to my saved trials
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1922
mi
from 98109
Royal Oak, MI
A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1922
mi
from 98109
Royal Oak, MI
Click here to add this to my saved trials
Multi-Center Study To Examine The Use Of Flex HD® And Strattice In The Repair Of Large Abdominal Wall Hernias
A Randomized, Prospective, Double-blind, Multi-Center Study To Examine And Compare The Outcomes Associated With The Use Of Flex HD®, A Human Acellular Dermal Matrix, And Strattice™, A Porcine Acellular Dermal Matrix Allograft, When Used As A Reinforcing Material In The Repair Of Large Abdominal Wall Hernias By A Component Separation Technique
Status: Enrolling
Updated:  12/31/1969
Pines Surgical
2713
mi
from 98109
Pembroke Pines, FL
Multi-Center Study To Examine The Use Of Flex HD® And Strattice In The Repair Of Large Abdominal Wall Hernias
A Randomized, Prospective, Double-blind, Multi-Center Study To Examine And Compare The Outcomes Associated With The Use Of Flex HD®, A Human Acellular Dermal Matrix, And Strattice™, A Porcine Acellular Dermal Matrix Allograft, When Used As A Reinforcing Material In The Repair Of Large Abdominal Wall Hernias By A Component Separation Technique
Status: Enrolling
Updated: 12/31/1969
Pines Surgical
2713
mi
from 98109
Pembroke Pines, FL
Click here to add this to my saved trials
Multi-Center Study To Examine The Use Of Flex HD® And Strattice In The Repair Of Large Abdominal Wall Hernias
A Randomized, Prospective, Double-blind, Multi-Center Study To Examine And Compare The Outcomes Associated With The Use Of Flex HD®, A Human Acellular Dermal Matrix, And Strattice™, A Porcine Acellular Dermal Matrix Allograft, When Used As A Reinforcing Material In The Repair Of Large Abdominal Wall Hernias By A Component Separation Technique
Status: Enrolling
Updated:  12/31/1969
CentraState Medical Center
2404
mi
from 98109
Freehold, NJ
Multi-Center Study To Examine The Use Of Flex HD® And Strattice In The Repair Of Large Abdominal Wall Hernias
A Randomized, Prospective, Double-blind, Multi-Center Study To Examine And Compare The Outcomes Associated With The Use Of Flex HD®, A Human Acellular Dermal Matrix, And Strattice™, A Porcine Acellular Dermal Matrix Allograft, When Used As A Reinforcing Material In The Repair Of Large Abdominal Wall Hernias By A Component Separation Technique
Status: Enrolling
Updated: 12/31/1969
CentraState Medical Center
2404
mi
from 98109
Freehold, NJ
Click here to add this to my saved trials
Multi-Center Study To Examine The Use Of Flex HD® And Strattice In The Repair Of Large Abdominal Wall Hernias
A Randomized, Prospective, Double-blind, Multi-Center Study To Examine And Compare The Outcomes Associated With The Use Of Flex HD®, A Human Acellular Dermal Matrix, And Strattice™, A Porcine Acellular Dermal Matrix Allograft, When Used As A Reinforcing Material In The Repair Of Large Abdominal Wall Hernias By A Component Separation Technique
Status: Enrolling
Updated:  12/31/1969
Washington Univ. in St. Louis/Barnes Jewish Hospital
1717
mi
from 98109
Saint Louis, MO
Multi-Center Study To Examine The Use Of Flex HD® And Strattice In The Repair Of Large Abdominal Wall Hernias
A Randomized, Prospective, Double-blind, Multi-Center Study To Examine And Compare The Outcomes Associated With The Use Of Flex HD®, A Human Acellular Dermal Matrix, And Strattice™, A Porcine Acellular Dermal Matrix Allograft, When Used As A Reinforcing Material In The Repair Of Large Abdominal Wall Hernias By A Component Separation Technique
Status: Enrolling
Updated: 12/31/1969
Washington Univ. in St. Louis/Barnes Jewish Hospital
1717
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Utility of Shearwave Elastography (SWE) and Non-Invasive Serum Biomarkers to Detect Fibrosis in Pediatric Patients With Liver Diseases
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hospital
1892
mi
from 98109
Houston, TX
Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Utility of Shearwave Elastography (SWE) and Non-Invasive Serum Biomarkers to Detect Fibrosis in Pediatric Patients With Liver Diseases
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hospital
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Arkansas Children's Hospital
1782
mi
from 98109
Little Rock, AR
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Arkansas Children's Hospital
1782
mi
from 98109
Little Rock, AR
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Mattel Children's Hospital UCLA, Department of Pediatric Gastroenterology
958
mi
from 98109
Los Angeles, CA
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Mattel Children's Hospital UCLA, Department of Pediatric Gastroenterology
958
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
1733
mi
from 98109
Chicago, IL
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children at IU Health
1868
mi
from 98109
Indianapolis, IN
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children at IU Health
1868
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
2485
mi
from 98109
Boston, MA
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Mott Children's Hospital (University of Michigan)
1901
mi
from 98109
Ann Arbor, MI
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Mott Children's Hospital (University of Michigan)
1901
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Childrens Mercy Hospitals & Clinics Pediatric Gastroenterology
1503
mi
from 98109
Kansas City, MO
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Childrens Mercy Hospitals & Clinics Pediatric Gastroenterology
1503
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
1366
mi
from 98109
Omaha, NE
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
1366
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
2402
mi
from 98109
Bronx, NY
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
2402
mi
from 98109
Bronx, NY
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
1966
mi
from 98109
Cincinnati, OH
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
1966
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
University of Tennessee Health Science Center Le Bonheur Pediatric Specialists
1863
mi
from 98109
Memphis, TN
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
University of Tennessee Health Science Center Le Bonheur Pediatric Specialists
1863
mi
from 98109
Memphis, TN
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Monroe Carell Jr. Children's Hospital at Vanderbilt
1970
mi
from 98109
Nashville, TN
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Monroe Carell Jr. Children's Hospital at Vanderbilt
1970
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Texas Childrens Hospital. Baylor College of Medicine
1892
mi
from 98109
Houston, TX
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Texas Childrens Hospital. Baylor College of Medicine
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Seattle Childrens Hospital Gastroenterology and Hepatology
2
mi
from 98109
Seattle, WA
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Seattle Childrens Hospital Gastroenterology and Hepatology
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin School of Medicine and Public Health Surgery
1617
mi
from 98109
Madison, WI
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin School of Medicine and Public Health Surgery
1617
mi
from 98109
Madison, WI
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Children´s Hospital of Alabama
2079
mi
from 98109
Birmingham, AL
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Children´s Hospital of Alabama
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital Los Angeles
957
mi
from 98109
Los Angeles, CA
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital Los Angeles
957
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Arnold Palmer Hospital for Children
2549
mi
from 98109
Orlando, FL
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Arnold Palmer Hospital for Children
2549
mi
from 98109
Orlando, FL
Click here to add this to my saved trials
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Great Ormond Street Hospital for Children
4782
mi
from 98109
London,
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Great Ormond Street Hospital for Children
4782
mi
from 98109
London,
Click here to add this to my saved trials
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated:  12/31/1969
University of California. Department of Surgery, Division of Transplantation
681
mi
from 98109
San Francisco, CA
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated: 12/31/1969
University of California. Department of Surgery, Division of Transplantation
681
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
1737
mi
from 98109
Chicago, IL
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
1737
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated:  12/31/1969
Schulze Diabetes Institute University of Minnesota Medical School
1391
mi
from 98109
Minneapolis, MN
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated: 12/31/1969
Schulze Diabetes Institute University of Minnesota Medical School
1391
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
2392
mi
from 98109
Lebanon, NH
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
2392
mi
from 98109
Lebanon, NH
Click here to add this to my saved trials
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati Medical Center
1963
mi
from 98109
Cincinnati, OH
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati Medical Center
1963
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated:  12/31/1969
Thomas E. Starzl Transplantation Institute, University Of Pittsburgh Medical Center
2132
mi
from 98109
Pittsburgh, PA
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated: 12/31/1969
Thomas E. Starzl Transplantation Institute, University Of Pittsburgh Medical Center
2132
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
Click here to add this to my saved trials